Oncology

Site-of-care considerations can pose challenges with these therapies.

Heidi Finnes, PharmD, BCOP, FHOPA, discusses the evolving landscape of treatment for patients with cutaneous malignancies and melanoma.

Oncology pharmacists can help normalize and encourage SOGI data collection.

Rose DiMarco, PharmD, BCPS, BCOP, shares insights into the evolving treatment landscape for patients with breast cancer with specific mutations.

An interdisciplinary discussion addresses the disparity in availability and use of these therapies across the continuum of care.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses the crucial role pharmacists play in providing supportive care for patients with cancer.

Jordyn P. Higgins, PharmD, BCOP, discusses the evolving treatment landscape for small cell lung cancer (SCLC).

Adagrasib receives accelerated approval for patients with previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC).

Questions arise around equity and revenue challenges.

There are numerous challenges with cell and gene therapies in oncology, such as accessibility, cost, and prior authorizations, as well as the need for improved education and training within the oncology community.

Tim Mok, PharmD, BCOP, BCPS, discusses innovative therapies that are changing the treatment options available for patients with hematologic malignancies.

Fostering communication and shared terminology is key.

Ryan Haumschild discusses the evolving treatment landscape for patients with multiple myeloma.

Additionally, the high cost of the cell therapy raises concerns for broader access.

Compared with standard of care chemoimmunotherapy, acalabrutinib with bendamustine and rituximab reduced risk of death or disease by approximately 27%.

Participants in the study had durable response for over 1 year, in addition to positive efficacy indicators.

Adopting the Planetary Health Diet may reduce overall risk of chronic disease and premature death.

A pharmacist examines the intersection of medicine and humanity.

Observation time on subsequent injections of subcutaneous daratumumab may be safely removed from institutional policies to reduce chair time.

The indication is for adult patients with primary advanced or recurrent endometrial carcinoma and is the third indication that pembrolizumab has received for this disease state.

The FDA approved blinatumomab for treatment of patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Durvalumab plus carboplatin and paclitaxel, continued with durvalumab monotherapy, decreased the risk of disease progression or death by 58%.

Persistent chemotherapy drug shortages challenge oncology providers. American Oncology Network employs a drug shortage committee for organized shortage management that involves pharmacists and interdisciplinary stakeholders.

As patients take more proactive roles in their health, they may feel too intimidated to discuss herbal medicinal use with their providers or may be unaware of potential interactions with their drug therapies.

Trametinib may become an alternative treatment to hematopoietic stem cell transplantation in patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML).

Brentuximab vedotin in combination with lenalidomide and rituximab had a favorable safety profile for patients with relapsed/refractory diffuse large B-cell lymphoma.

Repotrectinib has also shown significant efficacy in ROS1 fusion-positive non¬–small cell lung cancer (NSCLC), which was also studied in the TRIDENT-1 trial.

This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.